A randomised controlled trial investigating the effect of an intensive lifestyle intervention v. standard care in adults with type 2 diabetes immediately after initiating insulin therapy by Barratt, R. et al.
A randomised controlled trial investigating the effect of an intensive lifestyle
intervention v. standard care in adults with type 2 diabetes immediately after
initiating insulin therapy
Rachel Barratt1,2, Gary Frost1,3, D. J. Millward1 and Helen Truby4*
1University of Surrey, Guildford GU2 7XH, UK
2Royal Children’s Hospital, Melbourne, Australia
3Hammersmith Hospital NHS Trust, London, UK
4The Children’s Nutrition Research Centre, The University of Queensland, Herston 4029, Queensland, Australia
(Received 27 April 2007 – Revised 22 August 2007 – Accepted 30 August 2007 – First published online 15 January 2008)
Obesity and type 2 diabetes are inextricably linked. It is therefore unfortunate that insulin, the ultimate treatment to improve glycaemic control in
type 2 diabetes, is associated with significant weight gain. The aim of the present investigation was to ascertain whether a dietitian-led intensive
lifestyle intervention could attenuate weight gain associated with commencing insulin therapy. Subjects (n 50) with type 2 diabetes, within 4 weeks
of starting insulin therapy, were randomly allocated to a control or intervention group. The control group continued with standard care whilst the
intervention group followed a dietitian-led intensive lifestyle intervention. Over 6 months the control group gained 4·9 (SD 3·6) kg (P,0·001),
whilst the intervention group maintained their weight (20·6 (SD 5·1) kg (NS). The difference in weight change between the groups was 5·5 kg
(P,0·001). The control group had significant increases whilst the intervention group had slight decreases in: BMI (þ1·7 (SD 1·3) kg/m2
(P,0·001) v. 20·3 (SD 2·0) kg/m2 (NS)), waist circumference (þ5·3 (SD 5·0) cm (P,0·001) v. 20·4 (SD 5·2) cm (NS)) and percentage body
fat (þ1·5 (SD 2·0) % (P,0·001) v. 20·4 (SD 2·8) % (NS)). Differences between the groups for these parameters were significant (P,0·01).
Throughout the study, both groups experienced significant reductions in HbA1c, but only minor changes in blood lipids. The present study demon-
strates that weight gain is not an inevitable consequence of starting insulin therapy, but attenuation of the weight gain requires a high level of
intervention. The first 6 months to 1 year after initiating insulin therapy provides the ideal ‘window of opportunity’.
Type 2 diabetes: Obesity: Insulin therapy: Weight loss
Being overweight or obese has been identified as the primary
aetiological factor for the development of type 2 diabetes
(T2D) in adults(1). With the prevalence of obesity within most
populations rising, the WHO have predicted a 39% increase in
the global rate of diabetes from 2000 to 2030(2), although
recent reports suggest this may be an underestimate(3). The
cost implications to the health service for treatment of T2D
and its associated complications, both macro- and microvascu-
lar, are enormous. Historically, T2D was regarded as a ‘mild’
type of diabetes and was rarely treated with exogenous insulin.
The publication of the United Kingdom Prospective Diabetes
Study(4) provided the evidence to change treatment protocols,
as it demonstrated improving glycaemic control in T2D signifi-
cantly reduced the incidence of microvascular complications.
The UK Prospective Diabetes Study (UKPDS) found no signifi-
cant benefit of tight glycaemic control on the risk of developing
macrovascular disease and it was suggested that ‘follow up is
required to determine the risk-benefit ratio of the glycaemic
improvement, side effects, changes in body weight, and
plasma insulin concentration’(4,5). Treatment of T2D with
insulin is now widely used with the specific intention to gain
tighter control over blood glucose levels; insulin therapy is
now an integral part of management of this chronic and wide-
spread disease(6).
A commonly associated problem of commencing insulin
therapy in T2D is the associated weight gain. Studies that
have reported weight gains have observed an average gain
of 5–7 kg during the first 6 months of insulin therapy(7–9).
The reasons for the weight gain are not clearly understood
but in the already overweight or obese patient it is an unwel-
come occurrence. There is strong evidence in the non-diabetic
population that weight status itself and, more interestingly, the
process of weight gain in middle age increases CVD
risk(10–12). A directly proportional relationship between
weight gain after the age of 18 years and risk of CVD has
been documented(13). The health consequences of additional
weight gain associated with insulin therapy in T2D remain
unclear but are certainly a clinical challenge; with a back-
ground of high coronary risk it would be expected that further
weight gain induced by insulin therapy would increase that
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risk(13). However, this has yet to be proven. Very few studies
to date have investigated whether it is possible to limit the
weight gain experienced in patients with T2D starting insulin
therapy.
The primary aim of the present study was to investigate,
using a randomised controlled design, whether an intensive
programme of dietetic lifestyle and weight management
advice could be effective in reducing weight gain (achieving
weight maintenance) over the first 6 months of insulin treat-
ment in adults with T2D. The study hypothesis was that
adults with T2D who start insulin therapy and have access
to standard care would experience significant weight gain in
the first 6 months compared with those who undertook an
intensive lifestyle intervention. It was predicted that all
patients with T2D who commenced on insulin therapy
would experience an improvement in glycaemic control.
Methods
This trial was an unblinded randomised parallel intervention
study with a control group receiving standard care and the
intervention being a 6-month dietitian-led ‘Lifestyle change’
programme.
Recruitment took place at two tertiary hospitals in South
East England over a 2-year period (2004–5). Potential partici-
pants were identified by clinic staff as patients with T2D who
were about to be commenced on insulin therapy. These sub-
jects were then approached by the first author (R. B.) to ascer-
tain their willingness to participate in the study. All potential
participants had a diagnosis of T2D and were within 4 weeks
of starting insulin therapy. Subjects were included if they had
a BMI . 27 and , 50 kg/m2, aged between 18–75 years, able
to read and understand written English and able to give
informed consent. Exclusion criteria were the presence of
co-morbidities that may affect nutritional intake such as
inflammatory bowel disease, cancer, or renal or liver disease.
Individuals receiving medication to assist with weight loss
such as Reductil or Orlistat were also excluded. Females
were excluded if they were pregnant, lactating or planning a
pregnancy.
Protocol assignment
The primary outcome measure was change in weight over 6
months following initiation of insulin therapy. Power calcu-
lations were based upon an expected 3·5 kg difference in
weight change and standard deviation of 4 kg between the con-
trol and intervention groups. These calculations indicated that
twenty-one subjects in each group were required for a statisti-
cal strength of 80% and a significance of 0·05. Allowing for
an estimated drop-out rate of 20%, the total target number
to recruit was forty-eight subjects.
Randomisation
Subjects were randomly assigned to either the control or inter-
vention groups following a computer generated randomisation
table according to the order in which they were recruited.
There were two levels of stratification for sex (male and
female) and three levels of stratification for ethnicity (White,
Black and Asian).
Intervention
The intervention consisted of a 6-month intensive weight and
lifestyle intervention, the details of which are summarised in
Table 1. The intervention followed the ‘Lifestyle Clinic’ devel-
oped by Frost et al.(14), whichwas itself based upon the interven-
tions used in the US Diabetes Prevention Program(15). The
Lifestyle Clinic uses a holistic approach, aiming to improve
overall health through motivational interviewing, initiation of
patient empowerment and providing support and advice, with
the overall aim of achieving a 2092 kJ (500 kcal)/d energy defi-
cit. The subjects in the intervention group were seen by a regis-
tered dietitian (R. B.) on each clinic visit for continuity of care
and were seen six times over 6 months. Appointment times
were approximately 90min for the first appointment and
30min thereafter. At each appointment, individualised targets
were agreed and documented. Achievement of these targets
was checked at the subsequent appointment and motivational
interviewing techniques were used to encourage goal attainment
and maintenance of diet and lifestyle change.
Subjects in the control group continued to receive standard
care which followed general procedures that would occur
regardless of participation in the study. Standard care for
this population group at the time of the study included an
annual review in the endocrinology clinic, appointments and
phone contact with diabetes specialist nurses and, if required,
referral to other health professionals. Normal referrals or
appointments with allied health professionals, such as dieti-
tians, were unaffected for those in the control group but
were documented for the purposes of the study.
Study protocol and monitoring
All measurements were taken at baseline, and repeated after 6
months (except height). The anthropometric measurements
taken were height (cm), weight (0·1 kg electronic scales),
waist circumference (at naval level and correct to 0·2 cm) and
percentage body fat, which was estimated using bioelectrical
impedance analysis (Biospace InBody 3·0; Biospace, Soeul,
South Korea). BMI was calculated by dividing the weight in
kg by the height in metres squared. A number of measurements
were taken,which on an individual basis provide an indication of
CVD risk, but include measurements which can be used in com-
bination to estimate actual CVD risk through the use of a risk
model. These measurements include blood pressure and fasting
lipid levels. Blood pressure was measured using an electronic
sphygmomanometer (OmronM4;Omron,Kyoto, Japan).A fast-
ing venous blood sample was taken and subjects were asked to
refrain from strenuous exercise for 24 h before the appointment.
The plasma was analysed for HbA1c, glucose, total cholesterol,
HDL-cholesterol, LDL-cholesterol and TAG. The total choles-
terol:HDL-cholesterol ratio was calculated. The CV of all
plasma analysis were below 5%. To assess cardiovascular risk
the UKPDS risk engine(16) was used. Four estimated risk
scores were provided by the model; CHD, fatal CHD, stroke
and fatal stroke. These estimated CVD risk scores were calcu-
lated at the start and end of the study for each patient.
Statistical analysis
All data were tested for normality using the Kolmogorov–
Smirnov statistic. Primary analysis was carried out using an
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intention-to-treat analysis with baseline values carried forward
to account for missing values. Parametric tests were used for
the data found to be normally distributed. Intra-group analysis
was conducted using paired t tests, analysing the difference
between the start and end measurements. Paired t tests were car-
ried out on all the patients collectively and the control and inter-
vention groups separately. Independent t tests were used for
inter-group analysis, comparing the start and endmeasurements,
in addition to the absolute change and percentage change in each
parameter. Pearson x2 tests were used to explore the relation-
ships between categorical data, such as the randomised group
compared with the direction in which blood pressure changed.
ANOVA showed that site of recruitment did not affect weight
change nor attrition rate, so we analysed all data together.
Results
Participant flow
One hundred and eighty-nine patients were referred to the
study. Of those patients referred, 29% were recruited; 71%
did not enter the study due to either not meeting the study cri-
teria or the patient not wishing to participate. Fig. 1 shows the
flow of patients through the study. At the end of 6 months, the
overall attrition rate was 6% from the study.
Baseline data
Clinical and anthropometric characteristics were assessed at
baseline and there were no significant differences in sex, eth-
nicity, age, BMI, percentage body fat or HbA1c between the
control and intervention groups. The mean age of subjects
was 55·8 (SD 11·3) years. Subjects were centrally obese
(mean waist circumference 111·3 (SD 12·0) cm), had systolic
hypertension (143·0 (SD 23·5) mmHg) and poor glycaemic
control (mean HbA1c 9·7 (SD 1·4) mmol/l; mean glucose
11·4 (SD 3·2) mmol/l). According to The International Dia-
betes Federation worldwide definition(17) forty-seven (94%)
out of fifty subjects exhibited the metabolic syndrome.
There were no differences between the groups in the duration
of T2D (control 93·8 (SD 54) v. 96·8 (SD 64) months interven-
tion) or the time since commencing on insulin therapy (control
2·6 (SD 1·1) v. 2·3 (SD 1·1) weeks intervention) or the number
of insulin units prescribed (control 33·3 (SD 7·8) v. 29·5
(SD 9·8) units intervention).
The primary outcome measure was change in weight over
the first 6 months following the initiation of insulin therapy.
The control group gained a significant amount of weight 4·6
(SD 3·7) kg (P,0·001), whilst the intervention group managed
to maintain their original weight (mean weight change 20·6
(SD 5·0) kg). The difference in weight change between the
intervention and control groups equated to 5·2 kg which was
highly significant (P,0·001). In terms of percentage body
weight, the control group gained an additional 5·1% of body
weight in the 6 months after commencing insulin whilst the
intervention group lost 0·5% body weight (P,0·001).
All other anthropometric measures followed similar patterns
(see Table 2).
Over the 6 months of the study, both groups experienced a
significant reduction in HbA1c from baseline; the control
group had a reduction from 9·7 to 8·5% (P,0·001) and the
intervention group had a reduction from 9·6 to 8·7%
(P,0·05). There were no differences in the initial, final or
change in HbA1c or fasting glucose between the control and
intervention groups.
Table 1. Summary of topics and details of each topic covered in the ‘Lifestyle intervention’
Session Target or topic Details
1 Assess food intake Encourage patient to keep a detailed food diary, recording type of food with details, amount,
where eaten, feelings. To be kept continuously for at least 6 months
Increase physical activity Discuss appropriate activities, specific targets made with regards to amount and intensity.
Aiming for at least 5 £ 30 min moderate intensity bouts per week
2 Personalised energy prescription Energy requirements with 2092 kJ (500 kcal)/d deficit calculated. Designated number of
portions per food group with portion sizes to match energy requirements
Emotional eating Discussion and identification of trigger foods and situations. Ascertain coping methods
and strategies
3 Discussion on fat Discussion of types of fat, high-fat foods, identification of fat sources in diet from food diary,
education and advice aiming to reduce fat intake and improve fat quality by reduction
of saturated fat
Food labels Explanation of information provided on food labels, limits provided for fats, sugars and
salts per 100 g
4 Carbohydrates Description of carbohydrate types including GI and the effects of GI on blood glucose
Purchasing foods Ideals and information regarding eating out, shopping and preparation of food aiming to
reduce energy intake and maximise nutritional composition
Chain of events Discussion of the whole process of eating, from buying food, thoughts before eating,
preparation, consumption and postprandial feelings. Emotional implications and
coping strategies to prevent ‘negative’ chains
5 Hunger scale Discussion of feelings of hunger and use of placing hunger on an analogue scale.
Evaluation of reasons for eating, aiming to reduce unnecessary eating habits
Review of previous topics Clarification of all previous topics. Assessment of patient’s understanding, elucidation
of uncertainties
6 Review of achievements and results Repeat of initial measurements, analysis of positive changes achieved over past 6 months.
Discussion of future targets and incentives
Details of supportive organisations Details of support groups, weight-loss classes, websites and organisations available for
ongoing long-term support
GI, glycaemic index.
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There were only minor alterations in blood lipids through-
out the study. The lipid profile tended to worsen from the
initial reading to the endpoint in both groups but not signifi-
cantly, with the only favourable change occurring in the
total cholesterol:LDL-cholesterol ratio in the control group.
There were no statistical differences in any of the lipid
fractions between the groups either at the start or at the end
of the study.
There were small but non-significant alterations in blood
pressure throughout the 6-month study, but the direction of
change in blood pressure differed. The control group had a
mean increase in both systolic and diastolic blood pressure
Fig. 1. Participant flow.
Table 2. Summary of baseline anthropometric and biochemical data and the changes observed in the intervention and control groups after 6 months of
insulin therapy
(Mean values and standard deviations)
Baseline Change over 6 months
Control group
(n 25)
Intervention group
(n 25)
Control group
(n 25)
Intervention group
(n 25)
Mean SD Mean SD Mean SD Mean SD P *
Weight (kg) 90·2 16·9 96·6 15·6 4·6 3·7 20·6 5·0 ,0·001
BMI (kg/m2) 32·1 4·3 33·8 5·3 1·6 1·3 20·3 1·9 ,0·001
Waist circumference (cm) 109·7 11·0 112·8 13·0 4·9 5·0 20·4 5·0 ,0·001
Body fat (%) 35·4 7·4 37·5 10·2 4·5 6·3 20·1 7·1 0·027
Systolic BP (mmHg) 143·9 27·1 142·2 19·9 3·8 14·7 21·9 14·0 0·16
Diastolic BP (mmHg) 79·5 14·1 80·9 8·4 0·5 8·5 22·0 8·5 0·30
HbA1c 9·7 1·2 9·6 1·7 21·2 1·8 20·9 2·0 0·60
Total cholesterol (mmol/l) 4·6 1·0 4·1 0·8 20·05 1·0 0·2† 1·0 0·47
HDL-cholesterol (mmol/l) 1·2 0·3 1·1 0·3 20·07 0·2 20·02† 0·2 0·35
LDL-cholesterol (mmol/l) 2·6 0·8 2·3 0·8 20·1‡ 0·8 20·1† 0·6 0·40
Total cholesterol:HDL ratio 3·8 1·0 3·7 1·1 0·2‡ 0·8 0·1† 0·9 0·81
TAG (mmol/l) 1·8 0·9 1·9 1·1 0·1‡ 0·9 0·1 1·0 0·84
BP, blood pressure.
* Difference between control and intervention groups (t test).
†n 20.
‡n 24.
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of 3·8 and 0·5mmHg (NS) respectively, whereas the interven-
tion group had a mean decrease in both readings of 1·9 and
2·0mmHg (NS) respectively. Subjects in the control group
were statistically more likely to have an increase in blood
pressure whilst those in the intervention group were more
likely to have a decrease in blood pressure (x2 3·92;
P,0·05). Regardless of study group, overall, there was a posi-
tive correlation between percentage weight loss and fall in sys-
tolic blood pressure (r 0·288; P¼0·043).
There was an increase in the all CVD risk scores in both
groups in the 6 months following insulin therapy, except for
a very slight decrease in risk of a fatal CHD event in the
intervention group (see Fig. 2). The changes that occurred
over the 6 months and the difference between the groups
were not significant. The percentages of patients that had
decreases in CHD risk in the control and intervention
groups were 56·1 v. 61·1%, decreases in fatal CHD risk
60·9 and 66·7%, decrease in cerebral vascular accident
risk 21·7 and 22·2% and decreases in fatal cerebral vascular
accident risk 26·1 and 33·3% respectively. Pearson x2 anal-
ysis on the direction of change in risks was not significant.
An individual is considered at high risk of CHD if their
score exceeds 15%(18). At baseline, twelve subjects in the
control and nine in the intervention group exceeded this
score and at the end of the study there were two subjects
in each group that would be considered to have a high
CHD risk using this scoring system.
When there is a major change in treatment for T2D, such
as when insulin therapy is started, hospital protocols state
that the patient should be referred to a dietitian. Despite
this protocol, in the 6-month duration of the study only
18% of the whole cohort was seen by another dietitian
and 25% were referred to a dietitian at the time of com-
mencing on insulin. Fewer patients in the intervention
group were seen by another dietitian than those the in con-
trol group, potentially because staff knew that the patients
were receiving dietetic follow-up as part of the study and
therefore did not refer those in the intervention group as
frequently.
Discussion
The present study demonstrates that subjects with T2D can
gain a statistically and clinically significant amount of
weight in the 6 months after starting insulin. Those with
access to intensive intervention are able to maintain their orig-
inal body weight with the early introduction of dietetic care.
We conclude from these findings that weight gain is not
necessarily an inevitable consequence of starting insulin
therapy, but attenuation of the weight gain requires a high
level of intervention. The present study supports the sugges-
tion of Dickinson et al.(8) and UKPDS(6) that most weight
gain occurs soon after the initiation of insulin therapy and
slows with time, suggesting that the first 6 months to 1 year
after initiating insulin therapy is the ideal ‘window of oppor-
tunity’ for intensive lifestyle and diet advice to prevent weight
gain. These findings are similar to another intensive lifestyle
intervention in T2D that was carried out in individuals who
were not receiving insulin therapy(19).
The aim of starting insulin therapy is to improve glycaemic
control. It has been shown that a decrease in HbA1c is associ-
ated with reductions in microvascular complications(20,21),
with any reduction in HbA1c having benefits. However, the
relationship between HbA1c and macrovascular disease is
less defined. The American Diabetes Association has stated
that ‘the role of hyperglycaemia in cardiovascular compli-
cations is still unclear’(20). A recent meta-analysis of the
relationship between glycated Hb and CVD concluded that
‘improvements in glycaemia may lower the risk for cardiovas-
cular disease’(22), a finding which is not particularly compel-
ling. The lowest risk of CVD was associated with HbA1c
, 6%, a level suggestive of normal metabolism and rarely
achieved by individuals with T2D.
As was anticipated, insulin therapy significantly improved
glycaemic control, regardless of the level of dietetic inter-
vention. However, after 6 months of treatment both groups
had HbA1c that remained high (. 8%). The reduction in
HbA1c observed would be sufficient to reduce diabetic
symptoms, but insufficient to minimise the risk of diabetic
co-morbidities(22,23). Insulin therapy is undoubtedly a necess-
ary treatment for patients with T2D, particularly as b-cells
fail and glycaemic control deteriorates. However, it appears
that when used, treatment with insulin may not be suffi-
ciently intensive to achieve the targets for glycaemic
control. If insulin therapy is not used effectively the nega-
tive side effects, such as weight gain and the effects of
weight gain, may outweigh the minor benefits, potentially
negating its use.
The present study was not sufficiently powered to investi-
gate changes in blood lipids and therefore the minor changes
that occurred in the lipid profiles were not statistically signifi-
cant. The control group experienced a trend towards greater
deterioration in the risk of CHD, fatal CHD and fatal cerebral
vascular accident, but not in risk of cerebral vascular accident,
indicating that increasing body weight does impact negatively
upon overall CVD risk. The lack of significant difference can
in part be explained by the strict control of the CVD risk fac-
tors which are used for UKPDS risk engine calculation. It
would be expected that if a patient’s blood pressure, lipids
or glycaemic control exceeded the recommended target
levels, additional pharmacotherapy would be instigated to
Fig. 2. Mean calculated coronary heart disease (CVD) risk and cerebral vas-
cular accident (CVA) risk at baseline and after 6 months for control and inter-
vention groups. Values are means, with their standard errors represented by
vertical bars. ( ),Baseline control; ( ), end-point control; ( ), baseline inter-
vention; ( ), end-point intervention.
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counteract the rise and therefore reduce cardiovascular risk.
Indeed, eight (32%) of twenty-five patients in the control
group and three (12%) of the twenty-five patients in the inter-
vention group had additional antihypertensive agents or lipid-
lowering medications prescribed throughout the study period
and all patients had increases in insulin dose to improve gly-
caemic control. To fully assess the effects of initiating insulin
therapy and the associated weight gain no other changes
should be made to pharmacotherapy, but this would be
unethical.
A limitation of all studies that require participant consent is
selection bias. In the present study, recruitment into the study
proved to be difficult, with 59% of subjects who would have
been eligible refusing to participate. Extensive exploration of
why subjects refused to take part in a study where they had a
50% chance of receiving improved treatment was not possible.
It is perhaps a reflection of the general public’s lack of awareness
of the complications of diabetes or perhaps a lack of self-efficacy
about weight management that leads to patients not believing
that time spent attending an intensive lifestyle intervention is
worthwhile. It is interesting to note that while recruitment was
problematic, the overall attrition rate from the intervention
group was extremely small, indicating that once engaged in
the process of change, patients are keen to be involved. A
recent qualitative study showed that those with T2D were not
aware of the progressive nature of the disease and, although fear-
ful of starting insulin, adapted well on converting to insulin
therapy(24). The effect of selection bias could work in both direc-
tions; it could include patients who are actively trying to lose
weight or patients who feel that they are likely to experience sig-
nificant weight gain, such as those with recent weight loss as a
result of glucosuria. The similar degree of weight gain of those
in the control group as compared with previous retrospective
studies(19) indicates that the effect of selection bias, in this
case, was minimal.
The present study shows that it is possible to prevent the
negative side effect of weight gain following insulin therapy
through an intensive programme of diet and lifestyle advice.
With only one-quarter of the subjects referred for any dietetic
advice around the time of insulin commencement, it is not sur-
prising that the control group experienced weight gain. If an
intensive lifestyle intervention were made available for
patients with T2D as they start insulin therapy, targeted treat-
ment would be necessary to ensure the best use of this limited
resource to achieve optimal outcomes which are most likely to
relate to attenuation of weight gain rather than the expectation
of weight loss.
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